Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1975 1
1976 2
1994 3
1995 1
1996 3
1997 4
1998 4
1999 9
2000 6
2001 6
2002 8
2003 8
2004 8
2005 8
2006 8
2007 5
2008 5
2009 2
2010 4
2011 4
2012 3
2013 1
2014 1
2015 2
2016 2
2017 4
2018 2
2019 1
2020 1
Text availability
Article attribute
Article type
Publication date

Similar Articles for PMID: 11642379

108 results
Results by year
Filters applied: . Clear all
Page 1
Retreatment effect of NPe6 photodynamic therapy on the normal primate macula.
Nakashizuka T, Mori K, Hayashi N, Anzail K, Kanail K, Yoneya S, Moshfeghi DM, Peyman GA. Nakashizuka T, et al. Retina. 2001;21(5):493-8. doi: 10.1097/00006982-200110000-00012. Retina. 2001. PMID: 11642379
Photodynamic therapy of experimental choroidal neovascularization with a hydrophilic photosensitizer: mono-L-aspartyl chlorin e6.
Mori K, Yoneya S, Anzail K, Kabasawa S, Sodeyama T, Peyman GA, Moshfeghi DM. Mori K, et al. Retina. 2001;21(5):499-508. doi: 10.1097/00006982-200110000-00013. Retina. 2001. PMID: 11642380
Verteporfin photodynamic therapy retreatment of normal retina and choroid in the cynomolgus monkey.
Reinke MH, Canakis C, Husain D, Michaud N, Flotte TJ, Gragoudas ES, Miller JW. Reinke MH, et al. Ophthalmology. 1999 Oct;106(10):1915-23. doi: 10.1016/S0161-6420(99)90401-3. Ophthalmology. 1999. PMID: 10519585
Angiographic and histologic effects of fundus photodynamic therapy with a hydrophilic sensitizer (mono-L-aspartyl chlorin e6).
Mori K, Yoneya S, Ohta M, Sano A, Anzai K, Peyman GA, Moshfeghi DM. Mori K, et al. Ophthalmology. 1999 Jul;106(7):1384-91. doi: 10.1016/S0161-6420(99)00729-0. Ophthalmology. 1999. PMID: 10406627
Threshold and retreatment parameters of NPe6 photodynamic therapy in retinal and choroidal vessels.
Peyman GA, Kazi AA, Moshfeghi D, Unal M, Khoobehi B, Yoneya S, Mori K, Rivera I. Peyman GA, et al. Ophthalmic Surg Lasers. 2000 Jul-Aug;31(4):323-7. Ophthalmic Surg Lasers. 2000. PMID: 10928670
Effects of photodynamic therapy using verteporfin on experimental choroidal neovascularization and normal retina and choroid up to 7 weeks after treatment.
Husain D, Kramer M, Kenny AG, Michaud N, Flotte TJ, Gragoudas ES, Miller JW. Husain D, et al. Invest Ophthalmol Vis Sci. 1999 Sep;40(10):2322-31. Invest Ophthalmol Vis Sci. 1999. PMID: 10476799
Problems with and pitfalls of photodynamic therapy.
Peyman GA, Kazi AA, Unal M, Khoobehi B, Yoneya S, Mori K, Moshfeghi DM. Peyman GA, et al. Ophthalmology. 2000 Jan;107(1):29-35. doi: 10.1016/s0161-6420(99)00012-3. Ophthalmology. 2000. PMID: 10647715
Dose-related structural effects of photodynamic therapy on choroidal and retinal structures of human eyes.
Schlötzer-Schrehardt U, Viestenz A, Naumann GO, Laqua H, Michels S, Schmidt-Erfurth U. Schlötzer-Schrehardt U, et al. Graefes Arch Clin Exp Ophthalmol. 2002 Sep;240(9):748-57. doi: 10.1007/s00417-002-0517-4. Epub 2002 Aug 27. Graefes Arch Clin Exp Ophthalmol. 2002. PMID: 12271373
Photodynamic therapy with verteporfin for choroidal neovascularization caused by age-related macular degeneration: results of retreatments in a phase 1 and 2 study.
Schmidt-Erfurth U, Miller JW, Sickenberg M, Laqua H, Barbazetto I, Gragoudas ES, Zografos L, Piguet B, Pournaras CJ, Donati G, Lane AM, Birngruber R, van den Berg H, Strong HA, Manjuris U, Gray T, Fsadni M, Bressler NM. Schmidt-Erfurth U, et al. Arch Ophthalmol. 1999 Sep;117(9):1177-87. doi: 10.1001/archopht.117.9.1177. Arch Ophthalmol. 1999. PMID: 10496389 Clinical Trial.
Higher irradiance and photodynamic therapy for age-related macular degeneration (an AOS thesis).
Miller JW. Miller JW. Trans Am Ophthalmol Soc. 2008;106:357-82. Trans Am Ophthalmol Soc. 2008. PMID: 19277246 Free PMC article.
108 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page
Feedback